CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
DNAzyme targeting EBV-LMP1 (DZ1) +1 morebiological
Likely dose
DNAzyme targeting EBV-LMP1 (DZ1) 12 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01449942
NCT01449942Phase 2Completed
CompareCT.gov

Phase I/II Study of EBV-LMP1 Targeted DNAzyme in Nasopharyngeal Carcinoma

Xiangya Hospital of Central South University·interventional·Posted Oct 10, 2011·Updated Oct 10, 2011

In Brief

A Phase 2 clinical trial evaluating DNAzyme targeting EBV-LMP1 (DZ1) and Saline for Nasopharyngeal Carcinoma. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether an EBV-LMP1 targeted DNAzyme is effective in radiosensitization of nasopharyngeal carcinoma in combination with standard radiation therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasopharyngeal Carcinoma
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 10, 2011
Enrollment StartMay 1, 2009
Primary CompletionApr 1, 2011
Study CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 14.7 years ago

Interventions

DNAzyme targeting EBV-LMP1 (DZ1)biological

DZ1 in saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday. Dosage for each injection is 12 mg in 0.1 mL (200 micrograms per kilogram body weight. The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks.

Salineother

0.1 mL of saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday. The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks.